A recent autopsy analysis asserted that incretin drugs have the potential of increasing the risk for pancreatic cancer and for pancreatic neuroendocrine tumors. We examined the Network for Pancreatic Organ Donors with Diabetes (nPOD) database from which that analysis was derived. Our findings raise important questions about the comparability of the two groups of diabetes patients used for the analysis. Our review of the data available on the nPOD Web site and our reading of the earlier article lead us to the conclusion that the data, and the implications of the data, as expressed by the authors of the autopsy analysis are vastly overstated and are a misrepresentation of the information available.
Get full access to this article
View all access options for this article.
References
1.
DruckerDJ, NauckMA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006; 368:1696–1705.
2.
NauckMA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med, 2011; 124,Suppl:S3–S18.
3.
PatilHR, Al BadarinFJ, Al ShamiHA, BhattiSK, LavieCJ, BellDSH, O'KeefeJH. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol, 2012; 110:826–833.
4.
SunF, YuK, WuS, ZhangY, YangZ, ShiL, JiL, ZhanS. Cardiovascular safety and glycemic control of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus: a pairwise and network meta-analysis. Diabetes Res Clin Pract, 2012; 98:386–395.
5.
InzucchiSE, BergenstalRM, BuseJB, DiamontM, FerranniniE, NauckM, PetersAL, TsapasA, WenderR, MatthewsDR. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD): Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care, 2012; 35:1364–1379. Erratum in: Diabetes Care 2013;36:490.
NauckMA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? The benefits by far outweigh the potential risks. Diabetes Care, 2013; 36:2126–2132.
8.
GierB, ButlerPC. Glucagonlike peptide 1–based drugs and pancreatitis—clarity at last, but what about pancreatic cancer?JAMA Intern Med, 2013; 173:539–541.
9.
ButlerPC, ElashoffM, ElashoffR, GaleEAM. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? How safe are the GLP-1–based therapies?Diabetes Care, 2013; 36:2118–2125.
10.
ButlerAE, Campbell-ThompsonM, GurloT, DawsonDW, AtkinsonM, ButlerPC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes, 2013; 62:2595–2604.
11.
KahnSE. Incretin therapy and islet pathology—a time for caution. Diabetes, 2013; 62:2178–2180.
12.
Campbell-ThompsonM, WasserfallC, KaddisJ, Albanese-O'NeillA, StaevaT, NierrasC, MoraskiJ, RoweP, GiananiR, EisenbarthG, CrawfordJ, SchatzD, PuglieseA, AtkinsonM. Network for Pancreatic Organ Donors with Diabetes (nPOD): developing a tissue biobank for type 1 diabetes. Diabetes Metab Res Rev, 2012; 28:608–617.
WilliamsAJ, ThrowerSL, SequeirosIM, WardA, BickertonAS, TriayJM, CallawayMP, DayanCM. Pancreatic volume is reduced in adult patients with recently diagnosed type 1 diabetes. J Clin Endocrinol Metab, 2012; 97:2109–2113.
16.
Campbell-ThompsonM, WasserfallC, MontgomeryEL, AtkinsonMA, KaddisJS. Pancreas organ weight in individuals with disease-associated autoantibodies at risk for type 1 diabetes. JAMA, 2012; 308:2337–2339.
17.
AndreaA. Clinicopathological correlates of pancreatic intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases without pancreatic ductal adenocarcinoma. Mod Pathol, 2003; 16:996–1006.
18.
PanjwaniN, MulvihillEE, LonguetC, YustaB, CampbellJE, BrownTJ, StreutkerC, HollandD, CaoX, BaggioLL, DruckerDJ. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE–/– mice. Endocrinology, 2013; 154:127–139.
19.
GellingRW, DuXQ, DichmannDS, RomerJ, HuangH, CuiL, ObiciS, TangB, HolstJJ, FledeliusC, JohansenPB, RossettiL, JelicksLA, SerupP, NishimuraE, CharronMJ. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A, 2003; 100:1438–1443.
ZhouC, DhallD, NissenNN, ChenCR, YuR. Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor. Pancreas, 2009; 38:941–946.
22.
DerosaG, FranzettiIG, QuerciF, CarboneA, CiccarelliL, PiccinniMN, FogariE, MaffioliP. Exenatide plus metformin compared with metformin alone on β-cell function in patients with type 2 diabetes. Diabet Med, 2012; 29:1515–1523.
23.
GastaldelliA, BrodowsR, D'AlessioD. The effect of chronic twice daily exenatide treatment on β-cell function in new onset type 2 diabetes. Clin Endocrinol (Oxf), March14[Epub ahead of print]10.1111/cen.12199.
24.
MariA, ScherbaumWA, NilssonPM, LalanneG, SchweizerA, DunningBE, JauffretS, FoleyJE. Characterization of the influence of vildagliptin on model-assessed β-cell function in patients with type 2 diabetes and mild hyperglycemia. J Clin Endocrinol Metab, 2008; 93:103–109.
25.
American Diabetes Association calls for independent review of incretin therapy. www.diabetes.org/for-media/2013/american-diabetes-association-incretin-therapy.html. 2013 July 15.
26.
European Medicines Agency: Investigation into GLP-1 based diabetes therapies concluded. www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001856.jsp&mid=WC0b01ac058004d5c1. 2013 July 28.
